OncLive® On Air S11 Ep42: Exploring Lasofoxifene Plus Abemaciclib in ESR1+ Breast Cancer: Insights from ELAINE-3 With Sagar D. Sardesai, MBBS
Dec 16, 2024
Dive into the groundbreaking ELAINE-3 trial exploring lasofoxifene paired with abemaciclib for ESR1-mutant breast cancer. The discussion highlights trial design, patient eligibility, and enrollment challenges. Discover advancements in targeted therapies, including L-acestrin, and their impact on survival rates. The importance of shared decision-making in evolving treatment landscapes is emphasized, making this a must-listen for those interested in the future of breast cancer therapies.
AI Snips
Chapters
Transcript
Episode notes
Lasofoxifene Mechanism And Tolerability
- Lasofoxifene is a third-generation selective estrogen receptor modulator with a favorable tolerability profile.
- Sagar D. Sardesai notes expected adverse effects are mainly grade 1–2 hot flashes.
Clean Trial Design Targeting ESR1 Mutations
- ELANE-3 is a global randomized Phase III trial in ER+, HER2- metastatic breast cancer with ESR1 activating mutations.
- The trial compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib and measures progression-free survival.
Consider Eligibility Limitations Carefully
- Note the trial's unique eligibility focuses on ESR1 activating mutations to create a clean patient population.
- Excluding prior fulvestrant can affect which patients qualify for enrollment.